coteau ARQ.

ODTX

Odyssey Therapeutics, Inc.
$19.60
+$0.52 (2.73%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-8%+13%+34%+56%+77%May 8Oct 23Jul 3152w high $29.0552w low $15.10
ODTXSPY
Wall St. Highest PT $44.00 (+124.5%) Wall St. Avg PT $35.33 (+80.3%)
$16$23$31$39$47POC $18Hi $44Avg $35
Underwater Drawdown %Max DD -42.3%Current -31.8%
0.0%-42.3%
Relative Strength vs SPY+15.8% vs SPYOutperforming
+81%0%-81%
1W
+$2.43 (14.15%)
1M
−$1.16 (5.59%)
3M
+$0.94 (5.04%)
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
6 analysts · mean score 1.25
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$19.60
Average target$35.33
+$15.73 (+80.3%) upsideaverage target vs current price
CurrentAverageMedian
Low$27.00
Median$35.33
High$44.00
12-month Wall Street target range
Recent analyst rating changes · 10
Initiated
2026-10-12 · UBS started covering ODTX at Buy
Initiated
2026-10-09 · Raymond James started covering ODTX at Outperform
Initiated
2026-08-27 · HC Wainwright & Co. started covering ODTX at Buy
Reiterated
2026-08-07 · JP Morgan reiterated Overweight on ODTX
Reiterated
2026-06-18 · Oppenheimer reiterated Outperform on ODTX
Initiated
2026-06-02 · Cantor Fitzgerald started covering ODTX at Overweight
All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

Market value$941.9M
P/E (next 12 months, estimated)-4.7
52-week range$15.10 – $29.05
Dividend yieldNo dividend
Analyst consensusStrong Buy (6)
Average analyst price target$35.33 (+80%)

What they do

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for ODTX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

ODTX earningsNext report in 11 days
Next report
Thu Nov 5, 2026Time not confirmed
EPS consensus-$0.96 range -$1.07–-$0.81
Revenue consensus$0 7 analysts
Last 2 quarters · EPS vs estimate
Aug 6, 2026-$1.27est -$0.85−49.1%Below estimates
Jun 17, 2026-$6.75est -$1.28−427.0%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 03:16:27 ET
26-0626-08-6.750.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-06-30$959.0K–
2025-03-31$1.9M–

News & catalysts

More news
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
GlobeNewswire · Oct 20
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
GlobeNewswire · Oct 12
UBS Initiates Coverage on Odyssey Therapeutics With Buy Rating, $27 Price Target
MT Newswires · Oct 12
Raymond James Initiates Odyssey Therapeutics at Outperform
MT Newswires · Oct 09
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
GlobeNewswire · Oct 06
Rating changes
Initiated
2026-10-12 · UBS started covering ODTX at Buy
Initiated
2026-10-09 · Raymond James started covering ODTX at Outperform
Initiated
2026-08-27 · HC Wainwright & Co. started covering ODTX at Buy
Reiterated
2026-08-07 · JP Morgan reiterated Overweight on ODTX
Reiterated
2026-06-18 · Oppenheimer reiterated Outperform on ODTX
Initiated
2026-06-02 · Cantor Fitzgerald started covering ODTX at Overweight

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-24 03:16:27 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026